David Michael Johnson
David Michael Johnson's purchase track record
How the stock did after each of David Michael Johnson's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/16/2025 | AURA | $98K | +12.9% | -7.1% | +13.0% |
| 11/10/2023 | ZNTL | $168K | +16.9% | +27.4% | +18.3% |
| 11/7/2023 | AURA | $1.43M | +10.4% | +0.9% | +18.5% |
| 10/3/2023 | AURA | $168K | +5.4% | -13.7% | +23.1% |
| 1/5/2023 | AURA | $21K | -16.8% | +15.8% | +15.8% |
| 12/28/2022 | AURA | $39K | -5.5% | +25.4% | +15.7% |
| 12/1/2022 | AURA | $124K | -25.4% | -10.0% | +3.5% |
| 6/10/2022 | AURA | $716K | +2.7% | -19.1% | +0.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Aura Biosciences Announces Conference Participation and Inducement Grants. Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.
Transaction History
| ZNTL | ▲ Buy | Grant | 57,100 | $0 | 6/16/2026 | View on chart |
| AURA | ▲ Buy | Grant | 15,000 | $0 | 6/11/2026 | View on chart |
| AURA | ▲ Buy | Grant | 13,000 | $0 | 6/17/2025 | View on chart |
| ZNTL | ▲ Buy | Grant | 57,603 | $0 | 6/17/2025 | View on chart |
| AURA | ▲ Buy | Open Market | 20,000 | $98K | 5/16/2025 | View on chart |
| ZNTL | ▲ Buy | Grant | 48,429 | $0 | 6/21/2024 | View on chart |
| AURA | ▲ Buy | Grant | 10,500 | $0 | 6/20/2024 | View on chart |
| ZNTL | ▲ Buy | Open Market | 17,000 | $168K | 11/10/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 9,601 | $70K | 11/8/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 10,000 | $73K | 11/8/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 10,000 | $73K | 11/8/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 76,000 | $545K | 11/7/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 47,000 | $337K | 11/7/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 47,000 | $337K | 11/7/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 6,566 | $57K | 10/4/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 13,500 | $112K | 10/3/2023 | View on chart |
| ZNTL | ▲ Buy | Grant | 19,059 | $0 | 6/16/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 700 | $7K | 1/6/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 904 | $10K | 1/6/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 96 | $960 | 1/5/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 300 | $3K | 1/5/2023 | View on chart |
| AURA | ▲ Buy | Open Market | 2,000 | $20K | 12/28/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 2,000 | $20K | 12/28/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 5,000 | $62K | 12/1/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 5,000 | $62K | 12/1/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 7,000 | $98K | 6/13/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 7,000 | $98K | 6/13/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 20,000 | $280K | 6/13/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 3,000 | $45K | 6/10/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 3,000 | $45K | 6/10/2022 | View on chart |
| AURA | ▲ Buy | Open Market | 10,000 | $150K | 6/10/2022 | View on chart |
| ZNTL | ▲ Buy | Grant | 24,871 | $0 | 6/8/2022 | View on chart |
| AURA | ▼ Sell | Other | 139,672 | $0 | 11/2/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 4,892 | $323K | 10/4/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 7,904 | $526K | 10/4/2021 | View on chart |
| ZNTL | ▼ Sell | Open Market | 100 | $7K | 10/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.